affitope pd01a
Vaccineexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01568099)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-synucleinImmunity, active
SNCA immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- affitope pd01a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02758730 | Phase 1 | Apr 26, 2016 | Affiris AG, University of Tuebingen |
| NCT02618941 | Phase 1 | Feb 2, 2016 | Affiris AG |
| NCT02270489 | Phase 1 | Dec 11, 2014 | Affiris AG, Forschungszentrum Jülich, Institut National de la Santé Et de la Recherche Médicale, France, University of Bordeaux, University of Toulouse |
| NCT02216188 | Phase 1 | Aug 1, 2014 | Affiris AG |
| NCT01568099 | Phase 1 | Feb 1, 2012 | Affiris AG |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affiris AG | For profit | 5 | 5 | 1 | 2012 |
| Forschungszentrum Jülich | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Bordeaux | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1